Highlights
– The CONNEX programme (three identical phase 3 trials) found no significant improvement in cognition with 10 mg iclepertin versus placebo at 26 weeks (MCCB overall composite T-score adjusted mean difference 0.127; 95% CI -0.396 to 0.650; p=0.63).
– Iclepertin was well tolerated with on-treatment adverse event rates similar to placebo (66% vs 69%); no safety signal emerged.
